Program Schedule

80
HIV State-of-the-Art

Friday, October 10, 2014: 8:30 AM-10:00 AM
Room: The Pennsylvania Convention Center: 103-ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe advances in HIV treatment
  • outline strategies to evaluate changes in HIV treatment regimens for patients according to their treatment response
  • describe advances in hepatitis C treatment that may impact the management of co-infected patients with HIV

Target Audience: Public health practitioners, Members-in-training, Infectious diseases physicians, HIV specialists, HIV clinicians, Fellows, Clinicians

Tracks: HIV-STD-TB

Moderator:  Pablo Tebas, MD, Perelman School of Medicine, University of Pennsylvania

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-116-L02-P

Disclosures:

P. Tebas, None

P. Sax, AbbVie: Consultant and Scientific Advisor, Consulting fee
BMS: Investigator and Scientific Advisor, Consulting fee and Grant recipient
Gilead: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Scientific Advisor, Salary
ViiV: Consultant and Investigator, Consulting fee and Research support

D. Wohl, Gilead: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient
Janssen: Scientific Advisor, Consulting fee
Merck: Grant Investigator, Grant recipient
ViiV: Grant Investigator, Grant recipient

S. Naggie, Abbvie: Consultant, revenues from these activities are paid to the University. None of it is taken for personal income.
Achillion: Consultant, revenues from these activities are paid to the University. None of it is taken for personal income.
BMS: Consultant, revenues from these activities are paid to the University. None of it is taken for personal income.
Gillead: Consultant, revenues from these activities are paid to the University. None of it is taken for personal income.
Vertex: Consultant, revenues from these activities are paid to the University. None of it is taken for personal income.
IAS-USA: Collaborator and Member, Educational Activities or Lectures for this Company Generates Revenue for Duke
IDSA: Collaborator and Member, Educational Activities or Lectures for this Company Generates Revenue for Duke

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek